MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6501-252-256$20.00
Mol Pharmacol 65:252-256, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McGrew, L.
Right arrow Articles by Sanders-Bush, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGrew, L.
Right arrow Articles by Sanders-Bush, E.

RNA Editing of the Human Serotonin 5-HT2C Receptor Disrupts Transactivation of the Small G-Protein RhoA

Lori McGrew1, Raymond D. Price1, Elizabeth Hackler, Mike S. S. Chang2, and Elaine Sanders-Bush

Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee

The human serotonin 5-HT2C receptor undergoes adenosineto-inosine RNA editing at five positions, generating multiple receptor isoforms with altered G-protein coupling properties. In the current study, we demonstrate that RNA editing regulates the pattern of intracellular signaling. The non-edited human 5-HT2C receptor isoform INI activates phospholipase D via the G13 heterotrimer G-protein. We present evidence that transactivation of the small G-protein RhoA is required for phospholipase D activation. In contrast, neither transactivation of RhoA nor phospholipase D activation was detected in cells expressing the fully edited VGV isoform. The ability to activate phospholipase C is also reduced in VGV-expressing cells, but not to the extent found for the phospholipase D signal. We conclude that RNA editing represents a novel mechanism for regulating 5-HT2C receptor signaling to pathways linked to actin cytoskeletal organization and regulated exocytosis.


Received May 19, 2003; accepted October 15, 2003

Address correspondence to: Dr. Elaine Sanders-Bush, Vanderbilt University School of Medicine, Vanderbilt Brain Institute, 465 21st Avenue South, 8140 Medical Research Building III, Nashville, TN 37232-8548. E-mail: elaine.bush{at}vanderbilt.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
K. A. Berg, J. Dunlop, T. Sanchez, M. Silva, and W. P. Clarke
A Conservative, Single-Amino Acid Substitution in the Second Cytoplasmic Domain of the Human Serotonin2C Receptor Alters Both Ligand-Dependent and -Independent Receptor Signaling
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1084 - 1092.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Singh, R. A. Kesterson, M. M. Jacobs, J. M. Joers, J. C. Gore, and R. B. Emeson
Hyperphagia-mediated Obesity in Transgenic Mice Misexpressing the RNA-editing Enzyme ADAR2
J. Biol. Chem., August 3, 2007; 282(31): 22448 - 22459.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics